• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

New York regulator has concerns on CVS deal

Share:

October 1, 2018

  • The letter from NY Dept. of Financial Services chief Maria Vullo was sent last week to the Connecticut Insurance Dept.’s Katherine Wade. A hearing on the merger in Connecticut is set for Oct. 4.
  • In the letter, Vullo says the deal would have the two players with “incredibly” large market share, and create “real concerns” on pricing power.
  • Aetna, CVS
  • The Cigna /Express Scripts deal is also undergoing state reviews.

Date: October 1, 2018

Source: Seeking Alpha

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • FCC Surpasses $100M in Approved COVID-19 Telehealth Program ApplicationsFCC Surpasses $100M in Approved COVID-19 Telehealth Program Applications
  • BioLife Solutions to Acquire SAVSU TechnologiesBioLife Solutions to Acquire SAVSU Technologies
  • Knight to Acquire Latin American Pharma Firm for C$369MKnight to Acquire Latin American Pharma Firm for C$369M
  • Medical Devices: How to Master New Clinical Evaluation Report CriteriaMedical Devices: How to Master New Clinical Evaluation Report Criteria
  • Astellas to Acquire iota BiosciencesAstellas to Acquire iota Biosciences
  • Lunit scores contract to support NSW’s early breast cancer screening programmeLunit scores contract to support NSW’s early breast cancer screening programme
  • Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette SyndromeEmalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome
  • Mark Cuban Cost Plus Drug Company Announces First Health Plan PartnerMark Cuban Cost Plus Drug Company Announces First Health Plan Partner

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications